NCT02923180View on ClinicalTrials.gov

Neoadjuvant Enoblituzumab (MGA271) in Men With Localized Intermediate and High-Risk Prostate Cancer

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

33

Participants

Timeline

Start Date

February 14, 2017

Primary Completion Date

August 11, 2020

Study Completion Date

July 31, 2026

Conditions
Prostate Cancer
Interventions
DRUG

Enoblituzumab

Enoblituzumab 15mg/kg IV (in the vein) weekly for 6 doses beginning 50 days prior to radical prostatectomy.

Trial Locations (1)

21205

Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore

Sponsors

Collaborators (1)

MacroGenics
All Listed Sponsors
collaborator

MacroGenics

INDUSTRY

lead

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

OTHER

NCT02923180 - Neoadjuvant Enoblituzumab (MGA271) in Men With Localized Intermediate and High-Risk Prostate Cancer | Biotech Hunter | Biotech Hunter